HeyJaredJason L. Harris
- Indexed articles, last 90 days
- 28
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Psychiatry Advisor
- Top 5M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Sleep Fragmentation Is Associated With Poorer Cognition in Breast Cancer Survivors - Oncology Nurse Advisor (opens the original)
Read excerpt
Survivors of breast cancer who experience sleep fragmentation have consistently poorer objective cognition, according to research published in JNCI Cancer Spectrum.1 “Cancer-related cognitive dysfunction (CRCD) and insomnia are distressing for breast cancer survivors and commonly co-occur, yet little is known about how sleep patterns influence cognition,” study researchers explained. In this secondary analysis of a phase 2 trial (NCT04837820), the researchers aimed to characterize those associat
Sleep Fragmentation Is Associated With Poorer Cognition in Breast Cancer Survivors (opens the original)
Read excerpt
Survivors of breast cancer who experience sleep fragmentation have consistently poorer objective cognition, according to research published in JNCI Cancer Spectrum.1 “Cancer-related cognitive dysfunction (CRCD) and insomnia are distressing for breast cancer survivors and commonly co-occur, yet little is known about how sleep patterns influence cognition,” study researchers explained. In this secondary analysis of a phase 2 trial (NCT04837820), the researchers aimed to characterize those associat
PALOMA-2: Amivantamab-Lazertinib Maintains Long-Term Efficacy in EGFR-Mutated, Advanced NSCLC (opens the original)
Read excerpt
Subcutaneous amivantamab plus lazertinib has shown long-term, clinically meaningful and durable antitumor efficacy for patients with previously untreated, EGFR-mutated, advanced non-small cell lung cancer (NSCLC), according to long-term findings from the PALOMA-2 trial presented in a poster at the 2026 World Conference on Lung Cancer.1 The median follow-up was 33.1 months as of the July 2026 data cutoff. The median overall survival (OS) was not reached. The median OS rate was 83% at 24 months an
DREAMM-7: Belantamab Mafodotin, Bortezomib, Dexamethasone Triplet Sustained Superior Survival at 4 Years (opens the original)
Read excerpt
Long-term follow-up results showed that the belantamab mafodotin (belamaf), bortezomib, and dexamethasone (BVd) triplet was associated with improved survival compared with an anti-CD38–containing triplet for patients with relapsed/refractory multiple myeloma (RRMM), according to data presented in a poster during the Fourteenth Annual Meeting of the Society of Hematology Oncology 2026 Annual Meeting. Patients in the phase 3 DREAMM-7 trial (ClinicalTrials.gov Identifier: NCT04246047) received at l
DREAMM-7: Belantamab Mafodotin, Bortezomib, Dexamethasone Triplet Sustained Superior Survival at 4 Years - Oncology Nurse Advisor (opens the original)
Read excerpt
Long-term follow-up results showed that the belantamab mafodotin (belamaf), bortezomib, and dexamethasone (BVd) triplet was associated with improved survival compared with an anti-CD38–containing triplet for patients with relapsed/refractory multiple myeloma (RRMM), according to data presented in a poster during the Fourteenth Annual Meeting of the Society of Hematology Oncology 2026 Annual Meeting. Patients in the phase 3 DREAMM-7 trial (ClinicalTrials.gov Identifier: NCT04246047) received at l
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Psychiatry Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.